OpportunityTitle: Minor Use Minor Species Development of Drugs (R01)
Description: The Food &amp; Drug Administration&#8217;s (FDA) Center for Veterinary Medicine&#8217;s (CVM) Office of Minor Use &amp; Minor Species Animal Drug Development (OMUMS) was created after &#8220;The Minor Use and Minor Species Animal Health Act of 2004&#8221; (MUMS act) was signed into law. The MUMS act helps make more medications legally available to veterinarians and animal owners to treat minor animal species and minor uses in major animal species (MUMS drugs). Major species of animals are: horses, dogs, cats, cattle, swine, turkeys, and chickens. All other animal species (except humans) are minor species. A minor use is the intended use of a new animal drug in a major species for an indication that occurs infrequently and in only a small number of animals or in limited geographical areas and in only a small number of animals annually in the United States. To determine whether any particular use in a major species is a minor use, the FDA has established a specific &#8220;small number of animals&#8221; for each of the seven major animal species as follows: Horses-50,000 annually; Dogs-70,000 annually; Cats-120,000 annually; Cattle-310,000 annually; Swine-1,450,000 annually; Turkeys-14,000,000 annually; and Chickens-72,000,000 annually. Additional information about minor use and minor species is available on the FDA&#8217;s website for OMUMS. The FDA is authorized to provide grants for designated new animal drugs to assist in defraying the costs of qualified safety and effectiveness testing. The entity seeking approval of the new animal drug under investigation must hold a minor use or minor species &quot;designation&quot; granted by FDA/CVM/OMUMS for that drug for a specified intended use prior to application submission; the entity accomplishes this through a formal request to their Investigational New Animal Drug File (INAD). Qualified safety and effectiveness testing eligible for funding includes studies that support target animal safety or effectiveness, environmental safety, human food safety, and certain manufacturing studies, as well as the analytical method validation studies described below. FDA/CVM&#8217;s Office of New Animal Drug Evaluation (ONADE) must have accepted the proposed study protocol prior to application submission. The following manufacturing studies, as part of the qualified safety and effectiveness studies, are eligible for funding if FDA/CVM/ONADE has accepted the study protocol prior to application submission: A study to evaluate the stability of a MUMS drug A study to validate analytical methods associated with the manufacture of a MUMS drug A study to determine the homogeneity/segregation of an animal feed bearing or containing a MUMS drug A study to validate analytical methods for an animal feed bearing or containing a MUMS drug. A separate study to validate an analytical method prior to the conduct of an in-life human food safety study is also eligible for funding, if FDA/CVM/ONADE has accepted the study protocol prior to application submission. Applicants must explain how the proposed study will contribute to FDA approval or conditional approval of the product in the application&#8217;s &#8220;Significance&#8221; section of the Research Strategy (PHS 398 Research Plan). All funded studies are subject to the requirements of the Federal Food, Drug and Cosmetic Act (21 U.S.C. 331 et seq.), regulations issued under it, and applicable Department of Health and Human Services (HHS) statutes and regulations. There are two levels of funding available. The FDA will award grants up to $100,000 per year for up to 2 years (level one), or up to $150,000 per year for up to 3 years in certain cases (level two). Please note the dollar limitation will apply to total costs, not direct costs. Applications for the smaller level one grants ($100,000) may be for any routine safety or effectiveness study supportive of new animal drug approval or conditional approval of the designated product for the designated intended use. Study proposals for larger level two grants ($150,000) must be for necessary studies that are of unusual complexity, duration, or size. A third year of funding is available only for long-term toxicological studies.
GrantorContactEmailDescription: rene.vasquez@fda.hhs.gov
GrantorContactText: Rene Vasquez &lt;br/&gt;Grants Management Specialist &lt;br/&gt;Phone 301-796-3546